FDA Publishes ANDA Submission Guidance
The new guidance addresses FDA refuse-to-receive decisions in regards to impurity limits.
On August 24, 2016, FDA published guidance regarding the preparation and submission of original abbreviated new drug applications (ANDAs) and prior approval supplements (PASs) to ANDAs seeking approval of a new strength of the drug product. The agency addresses deficiencies in information provided by applicants about impurities, which would cause FDA to refuse to receive (RTR) an ANDA.
FDA may make an RTR decision if the agency feels the ANDA is not complete enough to review. The guidance states that deficiencies may include “failing to provide justification for proposed limits in drug substances and drug products for specified identified impurities that are above qualification thresholds; failing to provide justification for proposed limits for specified unidentified impurities that are above identification thresholds; and proposing limits for unspecified impurities (e.g., any unknown impurity) that are above identification thresholds.”
In the guidance, FDA clarifies how a failure to provide justification for proposed impurity limits may result in an ANDA being refused. The guidance offers recommendations for including the appropriate justification for impurities in ANDA submissions.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
